Coordination comittee

PDF version

From the PTEMI constitution date, the PTEMI Coordination Committee meets periodically in order to achieve the following objectives:

  • Development of PTEMI strategic action lines. Implement the periodical action plan and tracking and control of planned actions.

  • Advertise the platform: The comittee organizes the advertisement tasks for the platform through traditional media, mailings, web page, platform logo, etc …

  • Funding: The comittee activity, as well as the platform in general is needed of funding. Part of which is demanded through the present project.

  • Manage, organize and administer the platform.

  • Represent the platform everywhere either in front of the institutions or the general public.

  • Act as a negotiator in front of the european management organism.

The PTEMI'S Coordination Committee is composed in parital form by public sector representatives (7 members) and private (7 members). It can advice about and develop the strategic action lines of the Platform, as well as participate in advertisement activities. Two of its members: Javier Urzay and Ferran Sanz act as co-presidents of the Coordination Comittee

Both Co-presidents y the person asigned to their secretary are responsible for the day-to-day management of the Platform, support and update the annual work plan, adapting it to the possible variations and modifying it when needed in order to achieve the stablished objectives. Moreover, they are also responsible of the tracking and control of the tasks and reporting to the delegating authorities assigned as interlocutors by the National Plan of I+D+i

The committee meets regularly at least twice a year. When it is considered convenient, Ministers, ISCIII and CDTI delegates are invited.

The Coordination Committee composition and its relation with the tecnical secretary is described in the next figure.

Following some brief CV's of each of the PTEMI Coordination Committee members are presented.

Javier Urzay

Javier Urzay

Economist from the Universidad Autónoma of Madrid and MBA from the Instituto Adriano Olivetti of Ancona (Italy), has worked as enterprise strategic consultant in DBK (Databank Group) and has been General Subdirector of Technological Services and Technology Transfer in the Centro para el Desarrollo Tecnológico Industrial (CDTI), I+D promotion agency of the Ministry of Industry, Tourism and Commerce, until 2001, date when he entered FARMAINDUSTRIA as Director of Coordination, Studies and Associate Service. Nowadays he holds the position of General Subdirector of FARMAINDUSTRIA, working primary in economical, strategic and research tasks, as well as general tasks of coordination department . Javier Urzay coordinates the industry representation in the Plataforma Tecnológica Española de Medicamentos Innovadores.

Ferran Sanz

Ferran Sanz

Professor of Biostatistics and Biomedical Informatics at the Universitat Pompeu Fabra (UPF, Barcelona) and director of the IMIM-UPF joint Research Programme on Biomedical Informatics (GRIB, http://grib.upf.edu/). He authored more than 130 articles in ISI-indexed journals and supervised 18 PhD theses. He led nine EU-funded initiatives, as well as a STOA report for the European Parliament. Currently, he is coordinating an H2020 project on the translational and clinical application of Bioinformatics (MedBioinformatics), and is the academic coordinator of an IMI (Innovative Medicines Initiative) project on the in silico prediction of drug toxicity (eTOX). He is also partner in other ongoing IMI (EMIF, iPiE and TransQST) and H2020 projects (EU-ToxRisk and ELIXIR-EXCELERATE). Ferran Sanz is academic coordinator of the Spanish Technology Platform on Innovative Medicines (PTEMI) and vice-president of Bioinformatics Barcelona (BIB). He also coordinates the Biomedical Informatics Node of the Spanish Institute of Bioinformatics (INB). He was president of the European Federation for Medicinal Chemistry (EFMC) from January 2003 to December 2005 and vice-rector for Scientific Policy of the UPF from January 2004 to March 2009.

 


Jorge Beleta

Bachelor’s  Degree (1978) and Doctor in Sciences from the Universidad Autónoma de Barcelona (1986). After collaborating in several research programmes at the Biochemistry Department of the same University and a post-doctoral stay during 1986-87 at Imperial College (London) followed his professional career in industry. Initially devoted to the development of new enzymatic assays for clinical diagnosis, he joined Almirall later on as scientist of the Pharmacology Department.  There he has been in charge of the Departments of Molecular Pharmacology (1991) and Pharmacology, after the merger with Prodesfarma (1997), and subsequently Biology Director (2002). During this period has contributed to the discovery and characterisation of numerous compounds for the treatment of inflammatory or respiratory processes and pain. Among them, almotriptan and aclidinium  bromide can be highlighted. Both are currently being commercialised in Europe, the United States and other markets. Since 2009 he is the Director of Discovery Strategy and Alliances at Almirall, where he is in charge of establishing strategic collaborations between the Discovery area of the Company and other companies and public research institutions.

Mabel Loza

Mabel Loza

Doctor in Pharmacy from the Universidad de Santiago de Compostela (USC). Senior Lecturer in Pharmacology at the USC, where she leads a research and researching staff training group.  In the area of projects applied to medicine R&D, she is the author of six patents at different stages of procesing.  In the area of public research, she has authored over 60 publications in the journals with the greates influence in the area.  She has directed 8 doctoral theses and 28 postgraduate research works.  She participates continually in national and international conferences. She is an evaluator on research projects for national and European Institutions. She has taken part in 35 research projects financed with funding from the public and private institutions.  She has promoted the creation of a company (Pharmatool Digital Interactive), the creation of the USEF Platform for screening drugs and BIOPHARMA Group for translational research in psychiatry in Galicia.

Eduard Valentí

Eduard Valentí

Doctor in Chemical Sciences from the Universidad de Barcelona. Master in Business Management an Administration from ESADE and graduated of General Management Programme from the IESE.  For four years he worked as an educator in the Organic Chemistry departement at the Universidad de Barcelona. In 1988 he joined Laboratorios Dr.Esteve as manager of the Moleculas Modelling Unit. From 1993 to the present he has been the R&D Management Director at he laboratories. Likewise, he has authored 29 scientific publications and communications at international conferences and he has given 30 lectures and courses in the field of research management.

 Francisco Javier Carné Cladellas

Francisco Javier Carné Cladellas

Medical Doctor from the Universidad Autónoma de Barcelona, Specialist in clinical pharmacology. He has been a professor in the Pharmacology Department at the Universidad Autónoma de Barcelona and, during the 1990's, advisor for the Department of Pharmacy and Healthcare Products at the Ministry of Health and Consumer Affairs and member of the National Committee for the Evaluation of Medicines (CONEM). Since 1995 he is the expert advisor in medicine effectiveness and safety for the European Agency for the Evaluation of Medicinal Products (EMEA). He is also a member of the National Clinical Pharmacology Committee. Since 2000 he is the Service Manager for the Clinicla Pharmacology Unit at the Hospital Clínic i Provincial de Barcelona. He is currently the Spanish Representative for the European Clinical Research Infrastructure Netwoek (ECRIN) and the chairman of the Evaluation Committee for Medicines for Human Use (CODEM) at the Spanish Agency for Medical and Healthcare Products (AEMPS).

Javier Fernández Gadea

Javier Fernández Gadea

Doctor in Chemical Sciences from the Universidad Complutense de Madrid 1980. In 1985 he entered in Janssen and Cilag Spain to start up the Medicinal Chemistry Department. In 1990 he was promoted to Head of Medicinal Chemistry at Centro de Investigación Básica de Toledo being apponinted as Director of these centre in 2000. By 2003 he was promoted to Research Fellow of Jhonson & Jhonson and he became a full member of Management Board of Janssen-Cilag España. He leads projects in a wide variety of therapeutics areas since 1985, resulting in 14 NME's (New Molecular Entity) that entered clinical developmento so far. He is co-author of over 40 publications, 25 oral communications and invited lectures, and co-inventor in over 30 international patent applications. He is regular paricipant in Master and Doctorade Courses at several universities throughout Spain. Director of two doctoral theses and he has participated as invited jury member in the evaluation of 14 doctoral theses. He is a member of the Executive Committee of the Europen Federation of Medicinal Chemistry (EFMC) and Vice-president of the Spanish Royal Society of Therapeutic Chemistry (SEQT). He is also member of the Royal Spanish Society of Chemistry and of the Specialized Group of Organic Chemistry of this society. He has established in Spain through the participation of Hanssen-Cilag two scientific research prizes in different areas.

 Vicente Castell

Vicente Castell

Doctor of Science, Medical Doctor and Graduate in Pharmacy. Professor of Biochemistry and Molecular Biology in the School of Medicine at the Universidad de Valencia.  He has been a professor at the Universidad Autónoma de Madrid and at the University of Freiburg (Germany).  Doctorate studies at the CSIC, Federal Politechnic Institute of Zürich (ETH) and the Max-Plank Institut für Biophysikalische Chemie (Göttingen). Head of the Experimental Hepatology Unit, Research Centre at the Hospital Universitario La Fe de Valencia (1980). Eurpoean Award for Pharmaceutical Research (EFPIA) at the University of Heidelberg (1990). Director of the Foundation for Research at the H.U. La Fe, main area of research in hepatotoxicity mechanims due to drugs.  Author of 350 scientific works, 15 reviews and two books. He has participated as head researcher in 30 national projects  and 10 for the Eruopean Union, acting as coordinator on two occasions. Consultant for various national (FIS, PN I+D, CICYT) and international (COLIPA, ILSI INVITOX, ECVAM, DGXII/EU) institutions and agencies.  Founding member of the spin-off "Advancell, S.L.".
Estrella Soriano 

Estrella Soriano

University Degree in Biochemistry and a Doctoral Degree in Biology, from the University of Barcelona (Spain). She started her professional career in Sandoz A.G. (Switzerland) as Associate Investigator in Pharmacology and Preclinical Research, conducting research in receptors of the Central Nervous System. After four years working in the Faculty of Pharmacy of Barcelona, as Associate Professor in Human Physiology, she joined the Pharmaceutical Industry, developing different positions in the area of Clinical Research. Since year 2001, she is the Head of the Clinical Research Department, first in Pharmacia and then in Pfizer, with overall responsibility of the management of all the clinical trials from phase I to IV.

 

 

Antonio Portolés

Medical Doctor and Specialist in Clinical Pharmacology. Postgraduate Diploma in Design and Statistics in Health Sciences. Training and Quality Management. Professional Experience: Chief of Section of Clinical Pharmacology Extensive experience in design, evaluation and research development. He has elaborated research in all phases of development and use of drugs, especially in the early stages (phase I) Teaching and Research Experience: Associate Professor, University Complutense of Madrid and director of doctoral theses. Numerous articles in journals, conferences and books, co-editor of several books.

 

 Gonzalo París

 PhD in Pharmacy, Universidad Complutense of Madrid, Specialist in Clinical Biochemistry and in Industrial Pharmacy. Degree in Executive Management (IESE) and Senior Executive Development (INSEAD & Duke University). He started his professional activity as biochemical assistant lecturer and researcher at Universidad Complutense. He has worked in different pharmaceutical companies. Since 1989, he is Director of the Scientific Division at GlaxoSmithKline, S.A. Between 1996 and 2001 he was a member of the Management Committee of GlaxoWellcome-CSIC Cell and Molecular Biology Lab. He is author or co-author of a number of scientific papers and has been speaker in different meetings and courses related to pharmaceutical legislation, pharmaceutical industry, Research & Development, Innovation or Health Outcomes.

Fernando Peláez

Fernando Peláez

Bachelor’s Degree in Biology from the Universidad Complutense de Madrid in 1984 and carried out his PhD studies at the Centro de Biología Molecular (Universidad Autónoma de Madrid). In 1989 he joined the Centro de Investigación Básica de España (CIBE) - the basic research site of Merck, Sharp & Dohme in Spain, where he was responsible for fungal research within a screening group dedicated to discovering natural products with biological activity as a source of new leads in drug development. During this time he contributed to the discovery of many new molecules with therapeutic potential - some of which have progressed to different developmental stages as future drugs. Appointed as CIBE Director in 1999, he led a department with a staffing of 70 people for nine years; during this time he expanded his responsibilities within the company to cover other areas within the drug discovery process. Thus, his group also supported lead optimization projects carried out in other Merck research sites by implementing in vitro automated screens to assess safety and potential drug-drug interactions of candidate molecules. In December 2008 he joined the Spanish National Cancer Research Center (CNIO) as Director of the Biotechnology Programme, where he supervises the Core Units that provide CNIO research groups with access to a broad spectrum of cutting-edge technologies, including genomics, proteomics, transgenic mouse generation, inmunohistochemistry, molecular imaging and several others. Since October 2011 he is also the Head of the CNIO Director's Office. Fernando Peláez is author or co-author of 130 original papers, reviews and book chapters, and co-inventor of more than 40 patents on bioactive natural molecules. Since July 2014 he is Vicepresident of the Spanish Society of Biotechnology (SEBIOT)

Cristina Quiles

Cristina Quiles

Doctor of Medicine and Surgery at the Autonomous University of Barcelona, a specialist in cardiology. Senior Executive Program, ESADE, Barcelona 2007. Since 2005, CEO and cofounder of Neuroscience Technologies, a biotechnology company specializing in neuropathic pain research. Member of the Board of Directors of Bio Catalonia and member of Executive Group and Project Advisory Group BioHealth Barcelona Business School of the nomination of an Innovation Knowledge Community of the Euroepan Salut a Catalunya Institute of Innovation and Technology. She has authored several scientific publications


 Jose Manuel Vázquez Rodríguez 

Graduated in Medicine and Surgery at the University of Santiago de Compostela (1986). Specialist in Cardiology (1995). Doctor of Medicine, University of A Coruña (2010). Postgraduate courses in basic statistics, advanced statistics and research design (1997, Autonomous University of Barcelona). Master in Health Care Systems Management (2006, University of A Coruña). Certified in Management of Integrated Health Care Services (2011, ESADE Business School). In 1990 he began his training MIR in Cardiology in the Hospital Juan Canalejo of A Coruña. In 1994, was invited for six months to St. George's Hospital Medical School in London as a fellow of the Cardiological sciences department. In 1995 he joined the Unit of Cardiac Catheterization and Interventional Cardiology at the Hospital Juan Canalejo. Between 2001 and 2005 he was tutor of residents in Cardiology and member of the Continuing Medical Education Committee of the Spanish Society of Cardiology. Between 2006 and 2007 he was Medical Director of the University Hospital Juan Canalejo. Between 2009 and 2012 Director of Organization and Clinical Management at the University Hospital A Coruña, assuming responsibilities for teaching, research management and quality management as well as care management tasks. Since 2012 he is Coordinator of Teaching and R & D in the Health Care Area of A Coruña. Since December 2012 he is General Director of the Institute of Biomedical Research of A Coruña (INIBIC). Since June 2012 is the President of the Galician Society of Cardiology. Author or coauthor of 75 scientific articles and collaborator of web portals specialized in medicine

 

 

Amelia Martín Uranga

Amelia Martín Uranga

Graduated in Law from Deusto University and doctorate in Law, with a thesis on legal protection of biotechnology innovations. She joined FARMAINDUSTRIA in 2006 to manage the Spanish Technological Platform for Innovative Medicines, as Innovative Medicines Initiative mirror. She also is in charge of the coordination of  the “BEST” Project, as a strategic initiative promoted by the pharmaceutical industry with the aim of integrating all stakeholders, both public and private, to create an excellence based platform for clinical research in Spain. The objective is to boost R&D investment through monitoring the situation of the spanish Clinical Research process ;  identifying  the different practices and taking actions to improve  the efficiency and competitiveness position  in this field. This is a project made of more than 40 pharmaceutical companies executing over  90% of the clinical research promoted by the Spanish industry, 57 hospitals and 12 Regions in Spain. She also manages different biomedical research promotion programs such as the coordination of the Pharma-Biotech programme  being part of a public-private cooperation programs to promote the R&D of new drugs. She also coordinates different clinical trials working groups at FARMAINDUSTRIA.


She participates, as key note speaker, in numerous international and national Congresses, Seminars and Events in relation with clinical trial regulation ie.;CAEME (Cámara Argentina de Especialidades Médicas), BEST Project, and IMI.


Furthermore, she is an active member of Inovative Medicines Initiative Forum in Spain, not only to promote the Spanish participation in different IMI calls but to also make the IMI rules and procedures Known to different stakeholders.


She has a broad professional experience of more than 15 years teaching graduated and post graduated courses related with legal aspects in Biomedicine in prestigious national and international universities. She has developed her research work in the Interuniversity Chair in Law and the Human Genome -of which she is a scientific advisor, the UNED and the Sheffield Institute of Biotechnological Law and Ethics in the Sheffield University (UK). She has published several papers on legal aspects of Biomedicine.

Technical Secretary

Its principal mission is to support the Coordination Committee in day to day work. The Technical Secretary is located in the office that the PTEMI has in the Farmaindustria headquarters and has the personnel and infraestructure needed to acomplish its function.

The main functions of the Technical Secretary consist of:

  • Provide support to the Coordination Committee in the day to day management.
  • Maintain and update the web page of the PTEMI.
  • Write and distribute the Newsletter of the PTEMI.
  • Coordinate the organization of the Annual conferences and other events planned by the PTEMI.
  • Serve the working groups and participants of the PTEMI and transmit to the Coordination Committee the initiatives that emerge from the Participants Forum.
  • Represent the PTEMI in the designated events.
  • Report to the organizations involved in the PTEMI activities, particularly the MINISTERIO DE CIENCIA E INNOVACIÓN.

From the PTEMI foundation the management of the Technical Secretary is responsibility of Amelia Martín Uranga.

Esta página web se realizó en 2009 con apoyo financiero del Ministerio de Ciencia e Innovación y de los Fondos FEDER. Dentro del PN de investigación Científica, Desarrollo e Innovación Tecnológica 2008-2011. Ref. RET-90000-2008-001